NCT07133854Not yet recruiting
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
The Impact of Adipose Tissue Insulin Resistance and Abdominal Obesity on Hepatic Fatty Acid Metabolism in Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 21 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 6 Aug 2025
- Start date
- Sept 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Université de Sherbrooke
- Diseases
- Obesity, Type 1 diabetes
- NCT number
- NCT07133854
What you commit to
- Study type: Interventional
- Planned participants: 32
- From Sept 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing;
- Having participated to a research study with exposure to radiation in the last year before the start of the study
Other illness
- presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions;
- Being allergic to eggs
Lab values
- history of primary dyslipidemia (LDL-cholesterol over 5 mmol/L or TG over 10 mmol/L) or uncontrolled high blood pressure (over 160/100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol;
Other
- less than 70% of time in glycemic range (for T1D);
- current or planned pregnancy within the next 6 months;
- any contraindication to MRI.
- Smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day
Who the study is looking for
- 16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country/ethnic group-specific criteria (https://www.idf.org/e-library/consensus-statements/60- \[1\]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring.
- 16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status.
Age in the registry: 21 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre de recherche du CHUS Coordinator of this site? Confirm its status | Sherbrooke | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.